Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study

Table 5 Characteristics of hepatitis C virus patients who achieved sustained virological response after treatment with direct-acting antivirals while in the waiting list n (%)

	SVR after DAA before the WL n = 34	SVR after DAA in the WL n = 54
Age (yr)	58 ± 8	57.7 ± 8
Gender (male)	25 (73.5)	43 (79.6)
dec-HCV (yes)	15 (44)	44 (44.4)
MELD score before treament	-	13 ± 5
HCV genotype
1a	6 (17.6)	6 (11)
1b	17 (50)	34 (63)
2	2 (5.8)	2 (3.7)
3	7 (20.5)	7 (13)
4	2 (5.8)	5 (9.3)
Treatment regimens
Sofosbuvir	4 (11.7)	27 (50)
Sofosbuvir/Ledipasvir	23 (67.6)	18 (33.3)
Sofosbuvir/Daclatasvir	3 (8.8)	3 (5.5)
Sofosbuvir/Simeprevir	1 (2.9)	4 (7.4)
Other	5 (14.7)	2 (3.7)
Ribavirin use (yes)	1 (2.9)	37 (68.5)
MELD score after treament	12.3 ± 4	13 ± 6
Outcome
Waiting for LT	16 (47)	6 (11)
Delisted	1 (2.9)	10 (18.5)
LT	10 (29.4)	28 (51.8)
Drop out	5 (14.7)	2 (3.7)
Dead	2 (5.8)	8 (14.8)

SVR: Sustained virological response; DAA: Direct-acting antivirals; HCV: Hepatitis C virus; MELD: Model of End-Stage Liver Disease; LT: Liver transplantation.